Genmab A/S reaffirmed financial guidance for 2024. The company's revenue guidance is unchanged and expected to be in the previously disclosed guidance range of DKK 18.7 billion ? DKK 20.5 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,806 DKK | +0.50% |
|
-1.45% | -16.19% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.19% | 16.55B | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Reaffirms Financial Guidance for 2024